Amgen Inc.

Teijin Pharma Limited

Steven H Olson

Julio Cesar Medina

Xiaoqi Chen

Zhihua Ma

David John Kopecky

Xiaodong Wang

Richard V Connors

Julie Anne Heath

Zice Fu

Jeffrey Thomas Mihalic

Jeffrey Deignan

Jonathan B Houze

Paul John Dransfield

Vatee Pattaropong

Su-Jen Lai

Frank Kayser

Nobuko Nishimura

Lawrence R McGee

Ning Chen

Xiaohui Du

Alan C Cheng

Mikkel V Debenedetto

Kevin Chao Yang

Matthew R Kaller

Ted Charles Judd

Daniel B Horne

Simon J Hedley

Gayathri Swaminath

Wen-Chen Yeh

Yinhong Chen

Aarif Yusuf Khakoo

Robert P Farrell

Brian M Fox

Hilary Plake Beck

Daqing Sun

Xuelei Yan

Yosup Rew

Felix Gonzalez Lopez De Turiso

Michael D Bartberger

Ana Zurisadai Gonzalez Buenrostro

James S Harvey

Yihong Li

Philip M Roveto

Michael G Johnson

John Eksterowicz

Jason A Duquette

Darin J Gustin

Zhihong Li

Joel McIntosh

Jiasheng Fu

Malgorzata Wanska

Dustin L McMinn

Ming Yu

Jonathan Dante Low

Jiwen Liu

Brian Stuart Lucas

Yingcai Wang

Lars V Heumann

XianYun Jiao

Michael W Gribble, Jr

Xin Huang

Benjamin Fisher

SuJen Lai

Jiang Zhu

Patricia Lopez

Matthew Irvine Brown

Shon Booker

Ryan D White

Victor J Cee

Timothy David Cushing

Xiaolin Hao

Ryan Paul Wurz

Youngsook Shin

Lewis D Pennington

Kevin Yang

Stephanie Geuns-Meyer

Jason Brooks Human

Michael J Schmitt

Zihao Hua

Michael R Degraffenreid

Xiao Mei Zheng

Oleg Epstein

Ryota Nakajima

Nagasree Chakka

Howard Bregman

Keiko Shimada

Kosuke Sasaki

Lisa D Julian

Kazuhisa Okada

Hiroyuki Oono

Kenta Hibiya

Shuyan Yi

Christine Weathers

Jun Hirata

Shinji Kakuda

The present invention provides MDM2 inhibitor compounds of Formula I, or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor.

CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heteroaryl-substituted triazoles as APJ receptor agonists

Compounds of Formula (I) and Formula (II), pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula (I) and Formula (II) have the following structures: (I); (II). Intermediates (V) are also claimed. 

Triazole furan compounds as agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salt thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers have the following structure and are useful compounds in preparing small molecule agonists of the APJ Receptor: where the definitions of the variables are provided herein.

Compounds for use in preparing heterocyclic triazole agonists of the APJ receptor

Compounds of Formula I and Formula II, pharmaceutically acceptable salts thereof, stereoisomers of any of the foregoing, or mixtures thereof are agonists of the APJ Receptor and may have use in treating cardiovascular and other conditions. Compounds of Formula I and Formula II have the following structures: where the definitions of the variables are provided herein.

Heterocyclic triazole compounds as agonists of the APJ receptor

Compounds of Formula VII, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula VII have the following structure: where the definitions of the variables are provided herein.

Intermediates for preparing triazole agonists of the APJ receptor

The present invention provides MDM2 inhibitor compounds of Formula (I), or the pharmaceutically acceptable salts thereof, wherein the variables are defined above, which compounds are useful as therapeutic agents, particularly for the treatment of cancers. The present invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor of Formula (I). 

Heteroaryl acid morpholinone compounds as MDM2 inhibitors for the treatment of cancer

Methods of preparing compounds of Formula VI, salts thereof, tautomers thereof, or salts of the tautomers include cyclizing compounds of Formula V, salts thereof, tautomers thereof, or salts of the tautomers. Compounds of Formula VI and Formula V have the following structures: where the definitions of the variables are provided herein.

Methods for preparing triazole agonists of the APJ receptor

Compounds of Formula V, salts thereof, tautomers thereof, and salts of the tautomers are useful intermediates in the synthesis of agonists of the APJ Receptor. Compounds of Formula V have the following structure: where the definitions of the variables are provided herein.

The present invention provides MDM2 inhibitor compounds of Formula I, 

Piperidinone derivatives as MDM2 inhibitors for the treatment of cancer

Growing community of inventors

Millbrae, CA, United States of America

Steven H Olson